|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0003250,
umls-concept:C0023418,
umls-concept:C0030705,
umls-concept:C0205390,
umls-concept:C0332152,
umls-concept:C0376152,
umls-concept:C0599894,
umls-concept:C1274040,
umls-concept:C1504389,
umls-concept:C1515895,
umls-concept:C1521840,
umls-concept:C1522449,
umls-concept:C1522485,
umls-concept:C1708632,
umls-concept:C2603343
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2006-2-7
|
|
pubmed:abstractText |
We treated 20 adult patients with a (188) Re-labeled anti-CD66 antibody (mean marrow dose 13.3 Gy) prior to allogeneic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia or advanced chronic myeloid leukemia. The intensified conditioning was not associated with increased non-relapse mortality. No reduction in the incidence of relapse was observed in the context of a T-cell depleted graft (4-year overall survival: 29%).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1592-8721
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
91
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
285-6
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16461327-Adult,
pubmed-meshheading:16461327-Antigens, CD,
pubmed-meshheading:16461327-Bone Marrow,
pubmed-meshheading:16461327-Cell Adhesion Molecules,
pubmed-meshheading:16461327-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:16461327-Humans,
pubmed-meshheading:16461327-Immunoconjugates,
pubmed-meshheading:16461327-Leukemia,
pubmed-meshheading:16461327-Middle Aged,
pubmed-meshheading:16461327-Radioisotopes,
pubmed-meshheading:16461327-Rhenium,
pubmed-meshheading:16461327-Transplantation, Homologous,
pubmed-meshheading:16461327-Transplantation Conditioning
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Targeted marrow irradiation with radioactively labeled anti-CD66 monoclonal antibody prior to allogeneic stem cell transplantation for patients with leukemia: results of a phase I-II study.
|
|
pubmed:publicationType |
Letter,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II,
Clinical Trial, Phase I
|
